Press release
August 13, 2026
Eledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Eledon Pharmaceuticals, Inc. (ELDN)
Successful End-of-Phase 2 meeting with FDA supports advancement of tegoprubart into a global Phase 3 kidney transplantation trial, on track to initiate in late 2026 Long-term Phase 2 BESTOW data presented at ATC 2026 demonstrated sustained higher kidney function and improved patient-reported